JAK3 and ovarian cancer: Jiang B reported that miR-217 inhibited tumor-induced M2 macrophage polarization by targeting IL-6 and regulating the JAK3/STAT3 signaling pathway, probably providing an underlying therapeutic target in the treatment of ovarian cancer (Jiang et al., 2019).